Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 2/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311477 | 0.90 | SYK (0.52) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL25721690 | 0.90 | CTSL (0.59) | CASP3SYKCTSLCTSKCTSS | |
| SCHEMBL2498348 | 0.87 | CTSL (0.57) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL11657615 | 0.87 | SYK (0.59) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL20885259 | 0.87 | SYK (0.59) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL6791504 | 0.86 | SYK (0.56) | CASP1SYKCTSLCTSKCTSS | |
| SCHEMBL16847486 | 0.86 | SYK (0.61) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL29682213 | 0.85 | SYK (0.50) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL30672394 | 0.85 | SYK (0.50) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL1644413 | 0.85 | CTSL (0.55) | CASP1CASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-0920325-A3 | TETRAPEPTIDE DERIVATIVES OF DOLASTATIN AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-5939527-A | SYNTHETIC OLIGOPEPTIDE WITH BIOLOGICAL ACTIVITY OF DOLASTATIN FROM SEA HARE | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-17 | — | — | US | disclosed |
| EP-0920325-A2 | TETRAPEPTIDE DERIVATIVES OF DOLASTATIN AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0915908-A1 | DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5741892-A | Pentapeptides as antitumor agents | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-21 | — | — | US | disclosed |
| WO-1998004581-A1 | DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-05 | — | — | WO | disclosed |
| WO-1998004278-A2 | TETRAPEPTIDE DERIVATIVES OF DOLASTATIN AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | CASP1 450/4885CASP3 1846/4885CASP7 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.